FDA-cleared profile

AI-Rad Companion Organs RT

Siemens Medical Solutions U.S.A.

AI-Rad Companion Organs RT automatically contours predefined structures from DICOM images as an input to radiation-therapy planning workflows. VA50 added MR contouring with three T1 and six T2 target organs and updated CT contouring with 38 new organs; FDA materials limit MR validation to Siemens scanner data.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
AI-Rad Companion Organs RT automatically contours predefined structures from DICOM images as an input to radiation-therapy planning workflows. VA50 added MR contouring with three T1 and six T2 target organs and updated CT contouring with 38 new organs; FDA materials limit MR validation to Siemens scanner data.
FDA source Exact FDA submission Checked 2026-09-03
Intended users
Qualified and trained medical professionals who confirm, reject, and, where necessary, edit contours in a treatment-planning or interactive-contouring application.
FDA source Exact FDA submission Checked 2026-09-03
Care setting and population
Radiation-therapy departments in hospitals, clinics, and other qualified treatment-planning facilities.
FDA source Exact FDA submission Checked 2026-09-03
Workflow role
Automated predefined-structure contour generation before treatment planning
Public source Exact FDA submission Checked 2026-09-03
Required input
DICOM CT or MR image series; MR validation in VA50 was limited to Siemens Healthineers scanner data.
FDA source Exact FDA submission Checked 2026-09-03
Output and human action
DICOM RT Structure Set contours sent to a configurable DICOM node, commonly a treatment-planning system, after review in the results-confirmation workflow.
FDA source Exact FDA submission Checked 2026-09-03
Limitations
The device is not a standalone diagnostic or clinical decision-making system, is not intended to automatically detect or contour lesions, and requires review and editing before planning use. The FDA summary states that the added MR models were validated only on Siemens Healthineers scanner data.
FDA source Exact FDA submission Checked 2026-09-03

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232899
FDA source Exact FDA submission Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
FDA source Exact FDA submission Checked 2026-09-03
Anatomy
Multi-region
FDA source Exact FDA submission Checked 2026-09-03
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2024-04-03
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
DICOM CT or MR input, DICOM RTSTRUCT output, configurable DICOM-node transfer, organ-template configuration, and a web-based confirmation interface.
Public source Exact FDA submission Checked 2026-09-03
Deployment and data flow
FDA summaries describe cloud deployment for the early lineage and edge-plus-cloud deployment for later releases. Validate data routing, queue behavior, identity controls, downtime procedures, and the exact hosting model for the installed version.
Public source Exact FDA submission Checked 2026-09-03
Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-03

Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request architecture, data flow, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

Training and support
Only trained and qualified radiation-therapy professionals should operate the software and review, correct, and approve its outputs. Local onboarding must include release-specific limitations, failure examples, escalation, and competency documentation.
Public source Exact FDA submission Checked 2026-09-03
Monitoring and change control
Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.
Public source Exact FDA submission Checked 2026-09-03

Release and scope verification

VA50 added MR contouring with three T1 and six T2 target organs and updated CT contouring with 38 new organs; FDA materials limit MR validation to Siemens scanner data. Procurement should map the installed build, modules, models, anatomies, inputs, and outputs to K232899 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that an earlier cleared release includes them.

Interoperability acceptance

DICOM CT or MR input, DICOM RTSTRUCT output, configurable DICOM-node transfer, organ-template configuration, and a web-based confirmation interface.

exact submission · checked 2026-09-03

Test representative imports, exports, identifiers, orientation, geometry, structure names, units, failure handling, and round trips in the local environment.

Clinical acceptance

Use a signed local test set spanning supported anatomies, scanners, protocols, unusual or postsurgical anatomy, and small or complex structures. Measure edit burden, rejection, downstream plan effects, and reviewer agreement rather than relying only on average overlap metrics.

product family · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model total annual and per-plan cost against hands-on and elapsed time after review, correction, failed transfers, rework, support, upgrades, downtime, and any effect on plan quality or throughput.

product family · checked 2026-09-03

Vendor time-saving results are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.

product family · checked 2026-09-03

Trend failures and edits by exact software version, model, anatomy, scanner, protocol, and site.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
FDA summaries describe locked algorithms, software verification, DICOM testing, and release-specific validation of added structures. A multi-institutional publication and a blinded multi-vendor study support clinical usability while showing organ-level variation and continuing need for expert review; neither establishes autonomous use or patient-outcome benefit.
Public source Exact FDA submission Checked 2026-09-03
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Sensitivity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Specificity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

New CT organs

38 organs

New CT organs added versus VA40 in AI-Rad Companion Organs RT testing described in K232899.

Tested version: AI-Rad Companion Organs RT VA50

T1 MR target organs

3 organs

Target organs in the added T1 MR model in AI-Rad Companion Organs RT testing described in K232899.

Tested version: AI-Rad Companion Organs RT VA50

T2 MR target organs

6 organs

Target organs in the added T2 MR model in AI-Rad Companion Organs RT testing described in K232899.

Tested version: AI-Rad Companion Organs RT VA50

Structures in multi-institutional evaluation

33 organs

Organs evaluated by experienced radiation oncologists in Multi-region radiotherapy cases.

Tested version: AI-Rad Companion Organs RT product family; exact build not reported

Structures averaging at least 3.5

19 organs

Structures with mean clinical rating at or above 3.5 on a four-point scale in Product-family clinical evaluation.

Tested version: AI-Rad Companion Organs RT product family; exact build not reported

K232899 FDA performance package for AI-Rad Companion Organs RT

Manufacturer software verification and locked-model validation for release-specific CT or MR structures · Release-specific predefined CT or MR structures described in the FDA summary

exact submission · Tested version: AI-Rad Companion Organs RT VA50 · Sponsor or vendor study

K232899

Manufacturer evidence submitted for substantial equivalence. VA50 added MR contouring with three T1 and six T2 target organs and updated CT contouring with 38 new organs; FDA materials limit MR validation to Siemens scanner data.

Multi-institutional evaluation of AI-Rad Companion Organs RT

Multi-institutional clinical evaluation with three board-certified radiation-oncologist reviewers · Thirty-three organs at risk spanning multiple anatomic regions

product family · Tested version: AI-Rad Companion Organs RT product family; exact relationship to each cleared release must be checked · Independence not established

PMID 39023610

Nineteen structures averaged at least 3.5 on a four-point scale and the remainder at least 3.0; review author affiliations and exact software version before procurement use.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-03

No public list price for the exact cleared release was found. Obtain a written quote separating license basis, sites or users, enabled modules or models, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS Radiation Oncology Model material. Evaluate the product within the radiation-therapy planning service line using net staff time after review, plan quality, rework, throughput, implementation cost, and recurring cost.
Public source Not applicable Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K232899 by exact submission identifier.
Public source Exact FDA submission Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists. Maintain ongoing FDA and vendor surveillance.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
10Source classes checked
8Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials, current product-family materials, directly relevant clinical literature, reimbursement context, and exact-identifier recall candidates were reviewed. Pricing, final security architecture, contracted services, enabled modules or models, interoperability, and local acceptance remain organization-specific evidence. Automated exact-name discovery found 8 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, health technology guidance, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-03.

Alternatives

Related tools to compare

FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19
FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091....

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K242748

Oncospace

Oncospace, Inc.

Oncospace supports trained radiation therapy professionals with protocol configuration, machine-learning achievable-dose prediction, planning-objective exchange, and plan review...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-11